Back
Speaker illustration

Doctor Yuji Nishimoto

Toyonaka Municipal Hospital, Toyonaka (Japan)

Member of:

European Society of Cardiology

After graduating from Osaka University in 2010, I spent 2 years as a resident of internal medicine at Toyonaka Municipal Hospital, and after 2012, I spent 4 years as a fellowship of cardiovascular medicine at Osaka Police Hospital, and 3 years as a fellowship of cardiovascular medicine at Amagasaki General Medical Center (AGMC). From 2019, I became a chief physician of cardiovascular medicine at AGMC. I am an interventionist of cardiology. My principal research interests lie in the field of thrombosis including coronary artery, peripheral artery, and vein. As one of the members of the COMMAND VTE Registry, I have been engaged in analyzing epidemiological data especially focusing on the management of venous thromboembolisms. My academic performance is exceptional with experience of 26 original manuscripts (10 as a first author) and 8 case reports (6 as a first author) with several times experience of English oral presentation at international

Presentations Articles

Net clinical benefit of 18-month over 6-month rivaroxaban in patients with cancer and acute low-risk pulmonary embolism: Insight from the ONCO PE trial

Event: ESC Cardio-Oncology 2025

Topic: Diagnosis and Management of Cardiovascular Disease in Patients with Cancer

Session: Management of cardiovascular disease in cancer patients and survivors

Access
Like
Thumbnail

Application of DOAC Score for the risk-stratification of major bleeding in patients with venous thromboembolism on direct oral anticoagulants: insight from the COMMAND VTE Registry-2

Event: ESC Congress 2024

Topic: Venous Thromboembolism

Session: Venous thromboembolism: international perspectives

Access
Like
Thumbnail

Procedural volume and outcomes in patients with cardiogenic shock who received Impella: insight from the J-PVAD Registry

Event: ESC Congress 2024

Topic: Cardiogenic Shock

Session: Optimising the management of cardiogenic shock

Access
Like
Thumbnail

Effectiveness of an Impella versus intra-aortic balloon pump in patients who received extracorporeal membrane oxygenation: a nationwide inpatient database study

Event: ESC Congress 2024

Topic: Cardiogenic Shock

Session: Updates on mechanical circulatory support

Access
Like
Thumbnail

External validation of PE-SARD bleeding score for early major bleeding in patients with acute pulmonary embolism: Insight from the COMMAND VTE Registry-2

Event: ESC Congress 2023

Topic: Pulmonary Embolism (PE)

Session: Risk assessment, biomarkers, treatments of acute pulmonary embolism: are we able to impact outcomes?

Access
Like
Thumbnail

Trends in mechanical circulatory support use and outcomes of patients with cardiogenic shock in Japan, 2010-2020: a nationwide inpatient database study

Event: ESC Congress 2023

Topic: Cardiogenic Shock

Session: Prognostication and mechanical support in cardiogenic shock

Access
Like
Thumbnail

Risk factors of recurrence in patients with cancer-associated venous thromboembolism: from the COMMAND VTE Registry

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardio-Oncology

Session: New insights into cardio-oncology

Access
Like
Thumbnail

Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolisms: from the COMMAND VTE Registry

Event: ESC Congress 2020

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations ePosters

Access
Like
Thumbnail

Risk factors for major bleeding during prolonged anticoagulation therapy in cancer-associated venous thromboembolisms: From the COMMAND VTE Registry

Event: ESC Congress 2020

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations ePosters

Access
Like
Thumbnail

Thrombolysis with tissue plasminogen activator for patients with acute pulmonary embolisms in the real world: from the COMMAND VTE Registry

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Acute and anticoagulation

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources